E75-vaccine composition for transdermal administration
摘要
The invention provides a cancer vaccine composition for transdermal administration for inducing cellular immunity comprising (i) HER2/neu E75 peptide and/or a modified HER2/neu E75 peptide; and (ii) a first cellular immunity induction promoter.